AI Article Synopsis
- Alkaloids from the Papaverum somniferum are crucial for treating central nervous system diseases, especially pain management.
- The morphinan skeleton is the core structure of these opiate alkaloids and has been chemically enhanced over the past five decades to create more effective drugs targeting specific opioid receptors.
- This review highlights patent applications from early 2001 to mid-2002, discussing promising new drugs, innovative production methods for existing morphinans, and potential new drug formulations.
Article Abstract
Alkaloids extracted from the Papaverum somniferum are among the most powerfully acting and clinically used drugs for diseases of the central nervous system, in particular for pain. The basic ring system, common to these opiate alkaloids, is the morphinan skeleton, which in the last 50 years has been chemically manipulated to obtain compounds with improved potency and increased selectivity toward different populations of opioid receptors. Despite a huge amount of research, interest surrounding these compounds is still high. This review will discuss the patent applications published from January 2001 to June 2002, focusing on new chemical entities that could become drugs over the next few years, new chemical processes for the production of the morphinans currently used in therapy, novel formulations and combined compositions.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Bioactivities and Mechanisms of Action of Sinomenine and Its Derivatives: A Comprehensive Review.
Molecules
January 2024
College of Public Health and Health Management, Gannan Medical University, Ganzhou 341000, China.
Sinomenine, an isoquinoline alkaloid extracted from the roots and stems of , has been extensively studied for its derivatives as bioactive agents. This review concentrates on the research advancements in the biological activities and action mechanisms of sinomenine-related compounds until November 2023. The findings indicate a broad spectrum of pharmacological effects, including antitumor, anti-inflammation, neuroprotection, and immunosuppressive properties.
View Article and Find Full Text PDFAn efficient synthesis of 3-OBn-6β,14-epoxy-bridged opiates from naltrexone and identification of a related dual MOR inverse agonist/KOR agonist.
Bioorg Med Chem Lett
November 2012
University of New England, College of Arts and Sciences, Chemistry & Physics Department, Biddeford, ME 04005, USA.
In an effort to better understand the conformational preferences that inform the biological activity of naltrexone and related naltrexol derivatives, a new synthesis of the restricted analog 3-OBn-6β,14-epoxymorphinan 4 is described. 4 was synthesized starting from naltrexone in 50% overall yield, proceeding through the OBn-6α-triflate intermediate 8. Key steps to the synthesis include benzylation (96% yield), reduction (90% yield, α:β:3:2), followed by a one-pot triflation/displacement sequence (96% yield) to yield the desired bridged epoxy derivative 4.
View Article and Find Full Text PDFDesign, synthesis, and evaluation of biotinylated opioid derivatives as novel probes to study opioid pharmacology.
Bioconjug Chem
December 2008
Department of Chemistry and Biochemistry, 215 UCB, University of Colorado at Boulder, Boulder, Colorado 80309-0215, USA.
A generally applicable strategy of chemically labeling (-)-morphine (1) is described. The synthesis starts from commercially available starting materials and can be completed in two steps with an overall yield of 23%. In silico simulation and NMR results show that the binding of (-)-morphine to one of its molecular targets, toll-like receptor 4 (TLR4), was not affected by the modification.
View Article and Find Full Text PDFMorphinan derivatives--A review of the recent patent literature.
IDrugs
February 2003
NiKem Research Srl, Via Zambeletti 25, 20021 - Baranzate di Bollate, Milan, Italy.
Article Synopsis
- Alkaloids from the Papaverum somniferum are crucial for treating central nervous system diseases, especially pain management.
- The morphinan skeleton is the core structure of these opiate alkaloids and has been chemically enhanced over the past five decades to create more effective drugs targeting specific opioid receptors.
- This review highlights patent applications from early 2001 to mid-2002, discussing promising new drugs, innovative production methods for existing morphinans, and potential new drug formulations.
Molecular interactions between DPPC and morphine derivatives: a DSC and EPR study.
Int J Pharm
January 2003
Faculty of Medicine, Institute of Biophysics and Radiation Biology, Semmelweis University, Budapest VIII. Puskin u. 9, P.O. Box 263, H-1444 Budapest, Hungary.
The interaction between different morphine derivatives (morphine, codeine, N-methyl-morphine, N-methyl-codeine) and alpha-L-dipalmitoyl phosphatidylcholine (DPPC) liposomes was studied with differential scanning calorimetry (DSC) and electron paramagnetic resonance (EPR) spectroscopy. Small unilamellar DPPC-liposomes with the given morphine-derivative were prepared by sonication. The size distribution of liposomes was checked by dynamic light scattering (DLS).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!